Applying Multi-Omics technology in CAR T cell research
Chimeric antigen receptor T cell (CAR-T cell) therapy has proven to be very promising for blood disorders and, potentially, for solid tumors. In this approach, T cells taken from a patient or a donor are engineered to express a receptor on their surface, which allows them to target specific domains present on cancer cells. Single-cell multiomics techniques are being increasingly used in this exciting area to study cellular heterogeneity and molecular signatures. Multiomics techniques are also expected to provide an enhanced understanding of the interactions between CAR-T cells and the host immune system.
Here, we present a webinar by Dr. Fabio Luciani from the UNSW Cellular Genomics Future Institute, Sydney, Australia, describing the use of BD® AbSeq technology (with the ability to detect 40 markers simultaneously) and the BD Rhapsody™ Single-Cell Analysis System for analyzing cryo-preserved blood samples from patients undergoing CAR-T cell therapy. Dr. Luciani talks about the single-cell multiomics workflow, comprising sample preparation, cell type identification and gene expression analyses, that he used. Further, Dr. Luciani describes the bioinformatics workflow that was developed using the gene and protein expression data to analyze cellular composition. He also explains how the datasets from different specimens could be combined to get insights into cellular heterogeneity across samples.
